Search results

Records found: 2  
Your query: Author Sysno/Doc.kind = "^sllk_un_auth d018227 xcla^"

  1. 1.Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"

    Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"  / Sufliarsky J. .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379  
    C 3069
    article

    article

  2. 2.Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'

    Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'  / Šufliarsky J. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 222  
    C 3069
    article

    article



  This site uses cookies to make them easier to browse. Learn more about how we use cookies.

Accept allSettingsReject all